• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Shannon Ellis

Articles by Shannon Ellis

Vaccine developer Cansino pads coffers with $30M VC round

Nov. 4, 2015
By Shannon Ellis
SHANGHAI – Tianjin Cansino Inc., the company behind China's phase II Ebola vaccine, has received a $30 million investment from well-respected health care venture firms Qiming Venture Partners and Lilly Asia Ventures. It marks the second venture capital round for the 6-year-old company; in 2013, it accepted $10 million in a round led by Lilly Asia Ventures. (See BioWorld Today, Oct. 13, 2013.)
Read More

Wuxi accepts $3.3B deal to go private, plans to leave NYSE

Oct. 30, 2015
By Shannon Ellis

SHANGHAI – Acting on an offer first announced in April, Shanghai-based Wuxi Pharmatech Inc.'s board has accepted a $3.3 billion privatization bid, effectively taking China's largest CRO off the NYSE.


Read More

Wuxi accepts $3.3B deal to go private, plans to leave NYSE

Oct. 30, 2015
By Shannon Ellis

SHANGHAI – Acting on an offer first announced in April, Shanghai-based Wuxi Pharmatech Inc.'s board of directors has accepted a $3.3 billion privatization bid, effectively taking China's largest CRO off the NYSE.

Read More

China slowdown? Life sciences remains steadfastly immune

Oct. 28, 2015
By Shannon Ellis
SHANGHAI – Another year, another Shanghai October packed with conferences. But this time around, the angst of regulatory and reimbursement challenges has been replaced with a growing realization that the momentum of change is accelerating, even if there is considerable unease around how to make the most of it.
Read More

China slowdown? Life sciences remains steadfastly immune

Oct. 28, 2015
By Shannon Ellis
SHANGHAI – Another year, another Shanghai October packed with conferences. But this time around, the angst of regulatory and reimbursement challenges has been replaced with a growing realization that the momentum of change is accelerating, even if there is considerable unease around how to make the most of it.
Read More

Zai Lab digs deeper, sets up oncology discovery lab

Oct. 28, 2015
By Shannon Ellis
SHANGHAI – When Zai Lab Ltd. first came on the scene 18 months ago, nabbing global rights to two Sanofi SA assets for chronic respiratory disease, it looked like Zai would join the ranks of emerging virtual biotechs that use in-licensing to close China's unmet medical needs gap, but this time with a focus on oncology and autoimmune diseases.
Read More

Canbridge moves ahead with $10M in mezzanine financing

Oct. 28, 2015
By Shannon Ellis
SHANGHAI – Beijing-based Canbridge Life Science Inc., a biotech focused on developing Western drugs that treat China-specific diseases, has received an additional $10 million in VC financing, doubling the round it completed last year and putting the total venture financing at $20 million.
Read More

China's State Council promises to revolutionize drug development sector

Oct. 27, 2015
By Shannon Ellis

SHANGHAI – Pick an issue or an industry, China's complex problems can seem intractable with much-touted reforms dismally ineffectual. But with the power of China's top-down decision-making, there are times when the government sets a new course and far-reaching change follows swiftly if not necessarily smoothly. Over the summer, the State Council's edicts to the CFDA to fix the regulatory system by speeding up drug review times and getting better quality innovative drugs on the market looks set to have a dramatic effect on China's pharmaceutical sector.


Read More

Canbridge moves ahead with $10M in mezzanine financing

Oct. 27, 2015
By Shannon Ellis
SHANGHAI – Beijing-based Canbridge Life Science Inc., a biotech focused on developing Western drugs that treat China-specific diseases, has received an additional $10 million in VC financing, doubling the round it completed last year and putting the total venture financing at $20 million.
Read More

Zai Lab digs deeper, sets up oncology discovery lab

Oct. 27, 2015
By Shannon Ellis
SHANGHAI – When Zai Lab Ltd. first came on the scene 18 months ago, nabbing global rights to two Sanofi SA assets for chronic respiratory disease, it looked like Zai would join the ranks of emerging virtual biotechs that use in-licensing to close China's unmet medical needs gap, but this time with a focus on oncology and autoimmune diseases.
Read More
Previous 1 2 … 25 26 27 28 29 30 31 32 33 … 68 69 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 9, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 9, 2025.
  • Kidney disease illustration

    Prokidney produces positive phase II CKD data, thunderous stock surge

    BioWorld
    A mixed bag of top-line phase II data prompted stellar stock results for Prokidney Corp. and its chronic kidney disease (CKD) and diabetes therapy, rilparencel....
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • Hand pointing at digital M&A screen

    In a $10B deal, Merck buys cardio developer Verona

    BioWorld
    In the second largest M&A deal of the year, Merck & Co. Inc. has strengthened its cardiopulmonary portfolio with the $10 billion acquisition of London-based...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe